Connealy Pamela Yanchik Pyxis Oncology, Inc. (PYXS) insider trading activity

Connealy Pamela Yanchik is CFO & COO of Pyxis Oncology, Inc.. Currently has a direct ownership of 1.11 Million shares of PYXS, which is worth approximately $1.88 Million. The most recent transaction as insider was on Mar 26, 2024, when has been sold 328,710 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.11M

0% 3M change

42.06% 12M change

Total Value Held $1.88 Million

Connealy Pamela Yanchik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 26 2024	BUY Grant, award, or other acquisition	-	328,710 Added 22.84%	1,110,293 Common Stock
Nov 29 2023	SELL Payment of exercise price or tax liability	$51,728 $1.4 p/Share	36,949 Reduced 4.51%	781,583 Common Stock
Sep 28 2023	BUY Open market or private purchase	$14,960 $1.87 p/Share	8,000 Added 0.97%	818,532 Common Stock
Sep 27 2023	BUY Open market or private purchase	$11,888 $1.85 p/Share	6,426 Added 0.79%	810,532 Common Stock
Sep 25 2023	BUY Open market or private purchase	$20,040 $1.67 p/Share	12,000 Added 1.47%	804,106 Common Stock
Sep 22 2023	BUY Open market or private purchase	$8,700 $1.74 p/Share	5,000 Added 0.63%	792,106 Common Stock
Sep 07 2023	BUY Grant, award, or other acquisition	-	187,793 Added 19.36%	782,106 Common Stock
Mar 24 2023	BUY Grant, award, or other acquisition	-	209,803 Added 26.09%	594,313 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	43,493 Added 10.16%	384,510 Common Stock
Apr 14 2022	BUY Grant, award, or other acquisition	-	93,493 Added 21.52%	341,017 Common Stock
Mar 31 2022	BUY Grant, award, or other acquisition	-	247,524 Added 50.0%	247,524 Common Stock

Also insider at

IMVT

Immunovant, Inc. Healthcare

Chief Financial Officer

HSAQ

Health Sciences Acquisitions Corp 2 Financial Services

Director

CPY